TABLE 3.
Different variables and their associations with the hospital mortality of COVID‐19 in kidney‐transplanted patients in the bivariate analysis
| Characteristics | Number of studies | Mean ± SD | Odds ratio (95% CI) a | P value |
|---|---|---|---|---|
| Demographics | ||||
| Male (%) | 31 | 65.71 (13.91) | 1.01 (0.95‐1.07) | .75 |
| Mean age (year) | 31 | 64.0 (12.99) | 0.93 (0.86‐1.00) | .53 |
| Comorbidities | ||||
| Hypertension (%) | 27 | 74.93 (26.69) | 1.03 (1.00‐1.07) | .07 |
| Diabetes mellitus (%) | 23 | 31.21 (22.95) | 0.98 (0.94‐1.02) | .37 |
| Cancer (%) | 11 | 6.86 (10.39) | 0.98 (0.90‐1.06) | .60 |
| Heart disease (%) | 18 | 16.45 (19.45) | 1.04 (0.97‐1.12) | .26 |
| Lung disease (%) | 11 | 5.14 (7.99) | 1.04 (0.91‐1.19) | .53 |
| Imaging studies | ||||
| Lung involvement in CT/X‐ray (%) | 19 | 81.20 (24.12) | 0.96 (0.89‐1.03) | .23 |
| Unilateral lung involvement (%) | 12 | 17.94 (16.09) | 1.03 (0.96‐1.11) | .37 |
| Bilateral lung involvement (%) | 19 | 67.74 (23.18) | 0.97 (0.93‐1.02) | .31 |
| Changes in kidney transplant medications and medications for Covid‐19 | ||||
| Antimetabolite stopped (%) | 22 | 73.00 (30.09) | 0.98 (0.94‐1.02) | .27 |
| Antimetabolite dose reduction (%) | 6 | 13.83 (30.85) | 1.04 (0.96‐1.12) | .37 |
| Steroids stopped or lower the dose (%) | 11 | 15.72 (27.60) | 1.00 (0.97‐1.03) | .96 |
| Calcineurin stopped (%) | 22 | 42.96 (34.74) | 1.00 (0.98‐1.03) | .82 |
| Calcineurin dose reduction (%) | 5 | 24.62 (38.17) | 0.99 (0.96‐1.03) | .71 |
| Antiviral (%) | 19 | 41.15 (38.03) | 1.00 (0.98‐1.03) | .94 |
| Antibiotic (%) | 20 | 55.78 (41.46) | 1.00 (0.98‐1.03) | .75 |
| Hydroxychloroquine (%) | 22 | 70.44 (38.17) | 1.02 (0.99‐1.04) | .17 |
| Tocilizumab (%) | 15 | 19.31 (27.60) | 1.05 (0.97‐1.14) | .23 |
| IVIG (%) | 10 | 12.96 (21.52) | 0.99 (0.95‐1.03) | .49 |
| Signs and symptoms | ||||
| Fever (%) | 28 | 79.13 (17.78) | 0.99 (0.93‐1.05) | .69 |
| Cough (%) | 24 | 53.22 (29.42) | 0.98 (0.94‐1.02) | .33 |
| Dyspnea (%) | 26 | 50.80 (24.55) | 1.04 (1.00‐1.09) | .08 |
| Gustatory dysfunction (%) | 2 | 25.30 (17.42) | 1.02 (0.96‐1.09) | .55 |
| Myalgia (%) | 19 | 26.21 (23.96) | 1.02 (0.97‐1.07) | .41 |
| Fatigue (%) | 6 | 8.04 (19.79) | 0.92 (0.85‐1.00) | .04 |
| Nausea/vomiting (%) | 7 | 4.59 (8.77) | 0.95 (0.86‐1.06) | .37 |
| Morbidities and outcomes | ||||
| Intubated (%) | 17 | 23.11 (21.25) | 1.11 (0.98‐1.26) | .09 |
| Recover/discharge (%) | 27 | 54.63 (20.24) | 0.98 (0.93‐1.04) | .56 |
| Still in hospital (%) | 11 | 12.71 (20.56) | 0.97 (0.92‐1.01) | .14 |
a
Two‐sided 95% CI.